Orexin deficiency and narcolepsy

Current Opinion in Neurobiology

Volumn 23, Issue 5, 2013, Pages 760-766

  Sakurai, Takeshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMO PHENYL) 3 (2,2 DIMETHYL 4 PHENYL [1,3]DIOXAN 5 YL) UREA; 1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (2,4 DIBROMO PHENYL) 3 (2,2 DIMETHYL 4 PHENYL [1,2]DIOXAN 5 YL) UREA; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; ALMOREXANT; CAFFEINE; CENTRAL NERVOUS SYSTEM AGENTS; CLOMIPRAMINE; HISTAMINE H1 RECEPTOR; JNJ 10397049; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; SB 410220; SB 674042; SUVOREXANT; UNCLASSIFIED DRUG;

CATALEPSY; CATAPLEXY; CELL LOSS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; INSULIN SENSITIVITY; LOW DRUG DOSE; NARCOLEPSY; NERVE CELL NECROSIS; NEUROTRANSMISSION; NONHUMAN; NONREM SLEEP; OBESITY; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REM SLEEP; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; WAKEFULNESS;

ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEUROPEPTIDES; WAKEFULNESS;

EID: 84884351158     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2013.04.007     Document Type: Review

References (47)

1. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007, 8:171-181.
2. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998, 50:S16-S22.
3. Nishino S., Okura M., Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Review article. Sleep Med Rev 2000, 4:57-99. PubMed PMID: 12531161.
4. The International Classification of Sleep Disorders: Diagnostic and Coding Manual 2005, Association ASD, Rochester.
5. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., Qiu X., de Jong P.J., Nishino S., Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376. PubMed PMID: 10458611.
6. Nishino S., Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997, 52:27-78. PubMed PMID: 9185233. Epub 1997/05/01.eng.
7. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
8. Hara J., Beuckmann C.T., Nambu T., Willie J.T., Chemelli R.M., Sinton C.M., Sugiyama F., Yagami K., Goto K., Yanagisawa M., Sakurai T. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30:345-354.
9. Willie J.T., Chemelli R.M., Sinton C.M., Tokita S., Williams S.C., Kisanuki Y.Y., Marcus J.N., Lee C., Elmquist J.K., Kohlmeier K.A., et al. Distinct narcolepsy syndromes in orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38:715-730. PubMed PMID: 12797957. Epub 2003/06/12.eng.
10. Hondo M., Nagai K., Ohno K., Kisanuki Y., Willie J.T., Watanabe T., Yanagisawa M., Sakurai T. Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. Acta Physiol (Oxf) 2010, 198:287-294. PubMed PMID: 19694625. Epub 2009/08/22.eng.
11. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
12. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 9:991-997.
13. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., Cornford M., Siegel J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
14. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., Vankova J., Black J., Harsh J., Bassetti C., Schrader H., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
15. Kadotani H., Faraco J., Mignot E. Genetic studies in the sleep disorder narcolepsy. Genome Res 1998, 8:427-434.
16. Cvetkovic-Lopes V., Bayer L., Dorsaz S., Maret S., Pradervand S., Dauvilliers Y., Lecendreux M., Lammers G.J., Donjacour C.E., Du Pasquier R.A. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010, 120:713-719. PubMed PMID: 20160349. Pubmed Central PMCID: 2827962. Epub 2010/02/18.eng.
17. Lim A.S., Scammell T.E. The trouble with Tribbles: do antibodies against TRIB2 cause narcolepsy?. Sleep 2010, 33:857-858. PubMed PMID: 20614841. Pubmed Central PMCID: 2894423.
18. Hallmayer J., Faraco J., Lin L., Hesselson S., Winkelmann J., Kawashima M., Mayer G., Plazzi G., Nevsimalova S., Bourgin P. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009, 41:708-711. PubMed PMID: 19412176. Pubmed Central PMCID: 2803042. Epub 2009/05/05.eng.
19. Miyagawa T., Kawashima M., Nishida N., Ohashi J., Kimura R., Fujimoto A., Shimada M., Morishita S., Shigeta T., Lin L., et al. Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008, 40:1324-1328. PubMed PMID: 18820697. Epub 2008/09/30.eng.
20. Kornum B.R., Kawashima M., Faraco J., Lin L., Rico T.J., Hesselson S., Axtell R.C., Kuipers H., Weiner K., Hamacher A., et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011, 43:66-71. PubMed PMID: 21170044. Pubmed Central PMCID: 3019286. Epub 2010/12/21.eng.
21. Singh A.K., Mahlios J., Mignot E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J Autoimmun 2013, PubMed PMID: 23497937.
22. Scammell T.E., Willie J.T., Guilleminault C., Siegel J.M. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 2009, 32:111-116. PubMed PMID: 19189786.
23. Yamanaka A., Tsujino N., Funahashi H., Honda K., Guan J.L., Wang Q.P., Tominaga M., Goto K., Shioda S., Sakurai T. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 2002, 290:1237-1245. PubMed PMID: 11811995. Epub 2002/01/29.eng.
24. Huang Z.L., Qu W.M., Li W.D., Mochizuki T., Eguchi N., Watanabe T., Urade Y., Hayaishi O. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 2001, 98:9965-9970. PubMed PMID: 11493714. Pubmed Central PMCID: 55561. Epub 2001/08/09.eng.
25. Mochizuki T., Arrigoni E., Marcus J.N., Clark E.L., Yamamoto M., Honer M., Borroni E., Lowell B.B., Elmquist J.K., Scammell T.E. Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci U S A 2011, 108:4471-4476. PubMed PMID: 21368172. Pubmed Central PMCID: 3060231. Epub 2011/03/04.eng.
26. Zeitzer J.M., Nishino S., Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol Sci 2006, 27:368-374.
27. Mieda M., Hasegawa E., Kisanuki Y., Sinton C.M., Yanagisawa M., Sakurai T. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci 2011, 31:6518-6526.
28. Mochizuki T., Crocker A., McCormack S., Yanagisawa M., Sakurai T., Scammell T.E. Behavioral state instability in orexin knock-out mice. J Neurosci 2004, 24:6291-6300. PubMed PMID: 15254084.
29. Takahashi K., Lin J.S., Sakai K. Neuronal activity of orexin and non-orexin waking-active neurons during wake-sleep states in the mouse. Neuroscience 2008, 153:860-870. PubMed PMID: 18424001.
30. Mileykovskiy B.Y., Kiyashchenko L.I., Siegel J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005, 46:787-798. PubMed PMID: 15924864.
31. Lee M.G., Hassani O.K., Jones B.E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci 2005, 25:6716-6720. PubMed PMID: 16014733.
32. Schuld A., Hebebrand J., Geller F., Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 2000, 355:1274-1275.
33. Lammers G.J., Pijl H., Iestra J., Langius J.A., Buunk G., Meinders A.E. Spontaneous food choice in narcolepsy. Sleep 1996, 19:75-76.
34. Hara J., Yanagisawa M., Sakurai T. Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci Lett 2005, 380:239-242.
35. Funato H., Tsai A.L., Willie J.T., Kisanuki Y., Williams S.C., Sakurai T., Yanagisawa M. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab 2009, 9:64-76. PubMed PMID: 19117547. Pubmed Central PMCID: 2630400. Epub 2009/01/02.eng.
36. Brisbare-Roch C., Dingemanse J., Koberstein R., Hoever P., Aissaoui H., Flores S., Mueller C., Nayler O., van Gerven J., de Haas S.L., et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007, 13:150-155. PubMed PMID: 17259994. Epub 2007/01/30.eng.
37. Hoever P., de Haas S., Winkler J., Schoemaker R.C., Chiossi E., van Gerven J., Dingemanse J. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 2010, 87:593-600. PubMed PMID: 20376002. Epub 2010/04/09.eng.
38. Dietrich H., Jenck F. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology (Berl) 2010, 212:145-154. PubMed PMID: 20631993. Pubmed Central PMCID: 2937139. Epub 2010/07/16.eng.
39. Neubauer D.N. Almorexant a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Investig Drugs 2010, 11:101-110. PubMed PMID: 20047164. Epub 2010/01/05.eng.
40. Dugovic C., Shelton J.E., Aluisio L.E., Fraser I.C., Jiang X., Sutton S.W., Bonaventure P., Yun S., Li X., Lord B., et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009, 330:142-151. PubMed PMID: 19363060. Epub 2009/04/14.eng.
41. Morairty S.R., Revel F.G., Malherbe P., Moreau J.L., Valladao D., Wettstein J.G., Kilduff T.S., Borroni E. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE 2012, 7:e39131. PubMed PMID: 22768296. Pubmed Central PMCID: 3388080. Epub 2012/07/07.eng.
42. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649-4654.
43. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649-4654. PubMed PMID: 15070772. Pubmed Central PMCID: 384801. Epub 2004/04/09.eng.
44. Cox C.D., Breslin M.J., Whitman D.B., Schreier J.D., McGaughey G.B., Bogusky M.J., Roecker A.J., Mercer S.P., Bednar R.A., Lemaire W., et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methy l-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010, 53:5320-5332. PubMed PMID: 20565075. Epub 2010/06/23.eng.
45. Langmead C.J., Jerman J.C., Brough S.J., Scott C., Porter R.A., Herdon H.J. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004, 141:340-346. PubMed PMID: 14691055. Pubmed Central PMCID: 1574197. Epub 2003/12/24.eng.
46. Porter R.A., Chan W.N., Coulton S., Johns A., Hadley M.S., Widdowson K., Jerman J.C., Brough S.J., Coldwell M., Smart D., et al. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg Med Chem Lett 2001, 11:1907-1910. PubMed PMID: 11459658. Epub 2001/07/19.eng.
47. McAtee L.C., Sutton S.W., Rudolph D.A., Li X., Aluisio L.E., Phuong V.K., Dvorak C.A., Lovenberg T.W., Carruthers N.I., Jones T.K. Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett 2004, 14:4225-4229. PubMed PMID: 15261275. Epub 2004/07/21.eng.